GH-releasing peptides are at the forefront of research for tackling stubborn visceral fat and optimizing metabolism, and Tesamorelin is one of the most exciting advances in this arena. With a unique action on growth hormone (GH) secretion, Tesamorelin has gained attention not only for its stunning visceral fat reduction but also for how it helps revamp body composition and metabolic health. At Oath Research, we dig into the science behind this innovative peptide to help researchers understand its promise—and partners can find pure Tesamorelin among our catalog of research peptides. All products are strictly for research purposes and not for human or animal use.
Updated on March 4, 2026 — references verified, newer research added.
Understanding GH-Releasing Mechanisms and Tesamorelin
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), engineered to harness the body’s natural GH-releasing pathways. Unlike direct GH administration, which can disrupt feedback mechanisms, Tesamorelin stimulates the pituitary gland to release endogenous growth hormone. This cascade supports not just general GH-related processes but also specifically targets the challenging problem of visceral fat—the deep abdominal fat linked with metabolic risk.
Many clinical investigations show Tesamorelin’s specificity for reducing visceral adiposity, an effect driven by increased lipolysis. By acting upstream, Tesamorelin prompts the release of GH, which in turn boosts insulin-like growth factor 1 (igf-1), catalyzing a metabolic shift toward fat utilization and improved body composition.
Notably, in March 2025 the FDA approved EGRIFTA WR (tesamorelin F8), an 8× more concentrated formulation of the original FDA-approved tesamorelin product. EGRIFTA WR requires only weekly reconstitution rather than daily preparation—a meaningful improvement in research convenience and protocol compliance (FDA label 022505s020; Theratechnologies, 2025).
Tesamorelin’s Impact on Visceral Fat: Targeting What Matters Most
Research underscores that visceral fat isn’t just cosmetic—it’s metabolically active and strongly associated with complications like insulin resistance, elevated cholesterol, and cardiovascular disease. Traditional fat-loss strategies rarely differentiate between surface subcutaneous fat and the risky visceral depot. Here’s where a gh-releasing agent like Tesamorelin stands apart.
In pivotal studies, Tesamorelin led to significant, sustained visceral fat loss without dramatically impacting subcutaneous fat stores. This selective reduction matters, as shrinkage in the visceral compartment is linked to improved metabolic markers and a lower risk portfolio for research participants[1][2]. A 2014 JAMA randomized controlled trial (Stanley et al., PMID 25038357) found that tesamorelin decreased visceral fat by a mean of 34 cm² vs. +8 cm² in the placebo group over 6 months, while liver fat also fell significantly. You’ll find similar research support for AOD9604, another product at OathPeptides.com designed for investigations into fat metabolism.
A 2026 meta-analysis by Badran et al. (Obesity Research and Clinical Practice, PMID 41545261)—the most comprehensive synthesis of tesamorelin evidence to date—pooled data from five randomized controlled trials and quantified aggregate effects: visceral fat was reduced by 27.71 cm², trunk fat by 1.18 kg, hepatic fat by 4.28%, and lean body mass increased by 1.42 kg on average. Waist circumference declined 1.61 cm. Critically, no significant adverse effects on subcutaneous fat, BMI, or CD4+ counts were observed across all RCTs[5].
How GH-Releasing Tesamorelin Enhances Metabolism and Lipolysis
Directly boosting the body’s GH levels, Tesamorelin fosters a metabolic environment favoring fat burning. This metabolism enhancement can be measured by elevated rates of lipolysis—the biochemical breakdown of fats into free fatty acids for energy. This process is ramped up in the visceral area, supporting the observation of targeted abdominal fat reduction[3].
Importantly, the increase in igf-1 further amplifies anabolic processes and energy expenditure. While GH triggers lipolytic activity, IGF-1 supports the preservation of lean muscle, ensuring that the metabolic upswing translates to an improved body composition—more muscle, less fat.
Liver Fat and Hepatic Health: An Emerging Research Focus
Beyond visceral fat, tesamorelin has demonstrated significant hepatic benefits in rigorous trials. Stanley et al. (Lancet HIV, 2019, PMID 31611038) conducted a randomized, double-blind, multicenter trial (n=61, 12 months) showing tesamorelin produced a 37% relative reduction in hepatic fat fraction (P=0.016). Perhaps most compelling for metabolic research: fibrosis worsening occurred in only 10.5% of the tesamorelin group versus 37.5% of the placebo group—a striking difference suggesting hepatoprotective effects. No adverse glycemic effects were observed. These Lancet HIV-level data establish tesamorelin as a meaningful research tool not just for fat distribution but for broader metabolic liver health[4].
Tesamorelin in Modern HIV Regimens: 2024 INSTI Context
Historically, tesamorelin was studied primarily in the context of lipodystrophy caused by older antiretroviral regimens. A critical 2024 update changes that picture: Russo et al. (AIDS, 2024, PMID 38905488) published the first dedicated randomized trial of tesamorelin specifically in HIV patients receiving modern integrase strand transfer inhibitor (INSTI)-based therapy—now the global standard of care for HIV. INSTI regimens are associated with weight gain and adipose tissue dysfunction, raising new research questions for metabolic peptides. In this trial (n=31), tesamorelin produced a median VAT change of −25 cm² vs. +14 cm² with placebo (P=0.001), and hepatic fat fell 4.2% versus only 0.5% in the placebo group (P=0.01). Trunk-to-appendicular fat ratio improved significantly (P=0.03), and glycemic control was not adversely affected[3]. For research purposes, these findings extend tesamorelin’s established profile into the contemporary HIV treatment landscape.
GH-Releasing Strategies: Comparing Tesamorelin with Other Peptides
At Oath Research, we offer a broad spectrum of GH-releasing agents for research purposes—including CJC-1295 and Ipamorelin. However, Tesamorelin stands out due to its tailored action in minimizing visceral fat. For research teams interested in exploring synergistic effects, our CJC-1295/Ipamorelin blend can serve as a comparative control.
Like Tesamorelin, these peptides work through GH secretagogue pathways, but subtle differences in receptor affinity and kinetics may yield different patterns of fat loss or muscle gain. Side-by-side studies with Tesamorelin and other gh-releasing peptides—readily available from our research lineup—could help elucidate optimal protocols for manipulating body composition and metabolic markers.
Safe, Reliable Research—Not for Human or Animal Use
All peptides discussed, including Tesamorelin, are strictly for laboratory research. They are not approved for human or animal administration. Our commitment at OathPeptides.com is to supply verified compounds for controlled experimental settings only.
Exploring the IGF-1 Connection: Anabolic and Metabolic Benefits
One of the primary downstream effects of Tesamorelin’s gh-releasing action is a rise in igf-1 levels. IGF-1 is crucial in orchestrating anabolic growth, cell repair, and boosting basal metabolic rate. Elevated IGF-1 correlates with leaner mass retention, improved recovery, and an overall healthier body composition. For research teams exploring the nuances of anabolic signaling, IGF-1 assays are a useful endpoint to correlate with fat-loss and metabolic data.
Research also suggests a relationship between GHRH analog treatment and cognitive outcomes. Baker et al. (Archives of Neurology, 2012, PMID 22869065) found that GHRH analog administration in a 137-person RCT significantly improved executive function (P=0.005) and increased IGF-1 by 117% into physiological range. More recently, Ellis et al. (Journal of Infectious Diseases, 2025, PMID 39813152) tested tesamorelin for neurocognitive impairment in 73 HIV-positive abdominally obese adults over 6 months; tesamorelin significantly reduced waist circumference (median −2.7 cm, P=0.015), but cognitive improvement trended without reaching statistical significance (P=0.06 vs. P=0.673 between groups). For research purposes, these findings suggest tesamorelin’s IGF-1-mediated metabolic effects are consistent, while cognitive endpoints in this population require further investigation[6][7].
Real-World Research: Body Composition Outcomes
Clinical studies highlight that Tesamorelin consistently reduces abdominal visceral fat, and this benefit persists with continued use. Unlike many interventions where “yo-yo” effects are common, the fat reduction seen here is sustained when peptide exposure continues[2]. This reliability is crucial for research applications where metabolic studies run for several months.
Beyond fat loss, registered trials report incremental changes in waist circumference, improved lipid profiles, and—in some cases—modest gains in lean muscle mass. The 2026 Badran et al. meta-analysis (PMID 41545261) confirms these findings across five RCTs, with a mean lean body mass increase of 1.42 kg and waist circumference reduction of 1.61 cm, without significant changes in subcutaneous fat or adverse metabolic parameters[5]. This consistent improvement in body composition makes Tesamorelin a valuable reference compound for metabolic and endocrinology research.
Related Peptides for Research: AOD9604 and Lipolysis
For those investigating fat metabolism from various angles, AOD9604 (available at OathPeptides.com) is another synthetic peptide derived from hGH. AOD9604 has a distinct mechanism, directly stimulating lipolysis without influencing IGF-1 production, making it a meaningful comparator for Tesamorelin in metabolic studies. Check out AOD9604 for your research needs here.
Maximizing Research Validity: Bacteriostatic Water and Study Controls
Optimal results for your peptide research depend on proper reconstitution and storage. We recommend using only verified Bacteriostatic Water to ensure peptide stability and experimental consistency—find it in our catalog here.
FAQs: GH-Releasing Tesamorelin for Research
Q1: What is Tesamorelin and what makes it a unique gh-releasing peptide?
Tesamorelin is a synthetic analog of GHRH, designed to trigger the pituitary gland to secrete natural growth hormone. Its main distinction is the selective reduction of visceral fat, making it a well-regarded peptide for metabolic and body composition research[2].
Q2: How does Tesamorelin affect visceral fat compared to other approaches?
Unlike classic weight-loss interventions, Tesamorelin preferentially reduces deep abdominal (visceral) fat, often with minimal impact on subcutaneous fat. A 2026 meta-analysis (PMID 41545261) pooling five RCTs quantified this effect at a mean 27.71 cm² reduction in visceral fat[5].
Q3: What are the metabolic impacts of increased GH and IGF-1 from Tesamorelin?
Tesamorelin increases both GH and IGF-1, leading to heightened fat breakdown (lipolysis), improved energy utilization, and better preservation of lean muscle mass, all essential for healthy body composition.
Q4: Is Tesamorelin available for personal use?
No. All Tesamorelin and similar gh-releasing peptides from OathPeptides.com are provided strictly for research purposes and are not for human or animal use.
Q5: How can I ensure my peptide research is consistent?
Always source peptides from reputable suppliers and use proper controls, including verified bacteriostatic water and matched comparator peptides such as CJC-1295/Ipamorelin or AOD9604.
Conclusion: Partner with Oath Research for Cutting-Edge Peptide Solutions
GH-releasing Tesamorelin is leading the way in research on visceral fat reduction and enhanced metabolic health. Its ability to target deep abdominal adipose stores, stimulate lipolysis, preserve lean mass, and increase IGF-1 levels positions it as a gold standard for metabolic and body composition science.
Whether you’re advancing laboratory knowledge of peptide action or designing protocols to probe fat metabolism, Oath Research provides rigorously tested Tesamorelin and other verified peptides for experimental use. Explore our range of research-only compounds, including Tesamorelin, AOD9604, and Bacteriostatic Water—and trust our team for expertise, reliability, and compliance.
All products are strictly for research purposes and not for human or animal use.
—
References
1. Stanley TL, et al. “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.” JAMA. 2014. PubMed
2. Stanley TL, et al. “Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial.” Lancet HIV. 2019. PubMed
3. Russo HA, et al. “Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.” AIDS. 2024. PubMed
4. Stanley TL, et al. “Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial.” Lancet HIV. 2019. PubMed
5. Badran M, et al. “Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.” Obesity Research and Clinical Practice. 2026. PubMed
6. Baker LD, et al. “Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults.” Archives of Neurology. 2012. PubMed
7. Ellis RJ, et al. “Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.” Journal of Infectious Diseases. 2025. PubMed
For more peptide research insights and to browse our catalog, visit OathPeptides.com.
Rotator cuff injuries affect millions of people annually, ranging from athletes to weekend warriors to office workers. These shoulder injuries can be particularly challenging to heal due to the poor vascularization of tendon tissue. Recently, researchers have turned their attention to BPC-157, a synthetic peptide derived from a protective protein found in gastric juice, as …
A review of oxytocin receptor (OXTR) signaling mechanisms covering G-protein coupling selectivity, downstream second messenger generation, beta-arrestin recruitment, receptor desensitization kinetics, and the emerging concept of biased agonism at this class A GPCR.
Curious about how telomerase and epithalon peptide could redefine anti-aging and longevity? Explore the science behind maintaining optimal cellular health, circadian balance, and your lifelong wellness journey.
Exciting clinical trials have put thymosin alpha‑1, a powerful immune peptide, in the spotlight for its impressive ability to boost the body’s natural defenses. Discover how recent breakthroughs are reshaping immune peptide research and opening new doors for disease prevention strategies.
GH-Releasing Tesamorelin: Stunning Visceral Fat & Metabolism Boost
GH-releasing peptides are at the forefront of research for tackling stubborn visceral fat and optimizing metabolism, and Tesamorelin is one of the most exciting advances in this arena. With a unique action on growth hormone (GH) secretion, Tesamorelin has gained attention not only for its stunning visceral fat reduction but also for how it helps revamp body composition and metabolic health. At Oath Research, we dig into the science behind this innovative peptide to help researchers understand its promise—and partners can find pure Tesamorelin among our catalog of research peptides. All products are strictly for research purposes and not for human or animal use.
Updated on March 4, 2026 — references verified, newer research added.
Understanding GH-Releasing Mechanisms and Tesamorelin
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), engineered to harness the body’s natural GH-releasing pathways. Unlike direct GH administration, which can disrupt feedback mechanisms, Tesamorelin stimulates the pituitary gland to release endogenous growth hormone. This cascade supports not just general GH-related processes but also specifically targets the challenging problem of visceral fat—the deep abdominal fat linked with metabolic risk.
Many clinical investigations show Tesamorelin’s specificity for reducing visceral adiposity, an effect driven by increased lipolysis. By acting upstream, Tesamorelin prompts the release of GH, which in turn boosts insulin-like growth factor 1 (igf-1), catalyzing a metabolic shift toward fat utilization and improved body composition.
Notably, in March 2025 the FDA approved EGRIFTA WR (tesamorelin F8), an 8× more concentrated formulation of the original FDA-approved tesamorelin product. EGRIFTA WR requires only weekly reconstitution rather than daily preparation—a meaningful improvement in research convenience and protocol compliance (FDA label 022505s020; Theratechnologies, 2025).
Tesamorelin’s Impact on Visceral Fat: Targeting What Matters Most
Research underscores that visceral fat isn’t just cosmetic—it’s metabolically active and strongly associated with complications like insulin resistance, elevated cholesterol, and cardiovascular disease. Traditional fat-loss strategies rarely differentiate between surface subcutaneous fat and the risky visceral depot. Here’s where a gh-releasing agent like Tesamorelin stands apart.
In pivotal studies, Tesamorelin led to significant, sustained visceral fat loss without dramatically impacting subcutaneous fat stores. This selective reduction matters, as shrinkage in the visceral compartment is linked to improved metabolic markers and a lower risk portfolio for research participants[1][2]. A 2014 JAMA randomized controlled trial (Stanley et al., PMID 25038357) found that tesamorelin decreased visceral fat by a mean of 34 cm² vs. +8 cm² in the placebo group over 6 months, while liver fat also fell significantly. You’ll find similar research support for AOD9604, another product at OathPeptides.com designed for investigations into fat metabolism.
A 2026 meta-analysis by Badran et al. (Obesity Research and Clinical Practice, PMID 41545261)—the most comprehensive synthesis of tesamorelin evidence to date—pooled data from five randomized controlled trials and quantified aggregate effects: visceral fat was reduced by 27.71 cm², trunk fat by 1.18 kg, hepatic fat by 4.28%, and lean body mass increased by 1.42 kg on average. Waist circumference declined 1.61 cm. Critically, no significant adverse effects on subcutaneous fat, BMI, or CD4+ counts were observed across all RCTs[5].
How GH-Releasing Tesamorelin Enhances Metabolism and Lipolysis
Directly boosting the body’s GH levels, Tesamorelin fosters a metabolic environment favoring fat burning. This metabolism enhancement can be measured by elevated rates of lipolysis—the biochemical breakdown of fats into free fatty acids for energy. This process is ramped up in the visceral area, supporting the observation of targeted abdominal fat reduction[3].
Importantly, the increase in igf-1 further amplifies anabolic processes and energy expenditure. While GH triggers lipolytic activity, IGF-1 supports the preservation of lean muscle, ensuring that the metabolic upswing translates to an improved body composition—more muscle, less fat.
Liver Fat and Hepatic Health: An Emerging Research Focus
Beyond visceral fat, tesamorelin has demonstrated significant hepatic benefits in rigorous trials. Stanley et al. (Lancet HIV, 2019, PMID 31611038) conducted a randomized, double-blind, multicenter trial (n=61, 12 months) showing tesamorelin produced a 37% relative reduction in hepatic fat fraction (P=0.016). Perhaps most compelling for metabolic research: fibrosis worsening occurred in only 10.5% of the tesamorelin group versus 37.5% of the placebo group—a striking difference suggesting hepatoprotective effects. No adverse glycemic effects were observed. These Lancet HIV-level data establish tesamorelin as a meaningful research tool not just for fat distribution but for broader metabolic liver health[4].
Tesamorelin in Modern HIV Regimens: 2024 INSTI Context
Historically, tesamorelin was studied primarily in the context of lipodystrophy caused by older antiretroviral regimens. A critical 2024 update changes that picture: Russo et al. (AIDS, 2024, PMID 38905488) published the first dedicated randomized trial of tesamorelin specifically in HIV patients receiving modern integrase strand transfer inhibitor (INSTI)-based therapy—now the global standard of care for HIV. INSTI regimens are associated with weight gain and adipose tissue dysfunction, raising new research questions for metabolic peptides. In this trial (n=31), tesamorelin produced a median VAT change of −25 cm² vs. +14 cm² with placebo (P=0.001), and hepatic fat fell 4.2% versus only 0.5% in the placebo group (P=0.01). Trunk-to-appendicular fat ratio improved significantly (P=0.03), and glycemic control was not adversely affected[3]. For research purposes, these findings extend tesamorelin’s established profile into the contemporary HIV treatment landscape.
GH-Releasing Strategies: Comparing Tesamorelin with Other Peptides
At Oath Research, we offer a broad spectrum of GH-releasing agents for research purposes—including CJC-1295 and Ipamorelin. However, Tesamorelin stands out due to its tailored action in minimizing visceral fat. For research teams interested in exploring synergistic effects, our CJC-1295/Ipamorelin blend can serve as a comparative control.
Like Tesamorelin, these peptides work through GH secretagogue pathways, but subtle differences in receptor affinity and kinetics may yield different patterns of fat loss or muscle gain. Side-by-side studies with Tesamorelin and other gh-releasing peptides—readily available from our research lineup—could help elucidate optimal protocols for manipulating body composition and metabolic markers.
Safe, Reliable Research—Not for Human or Animal Use
All peptides discussed, including Tesamorelin, are strictly for laboratory research. They are not approved for human or animal administration. Our commitment at OathPeptides.com is to supply verified compounds for controlled experimental settings only.
Exploring the IGF-1 Connection: Anabolic and Metabolic Benefits
One of the primary downstream effects of Tesamorelin’s gh-releasing action is a rise in igf-1 levels. IGF-1 is crucial in orchestrating anabolic growth, cell repair, and boosting basal metabolic rate. Elevated IGF-1 correlates with leaner mass retention, improved recovery, and an overall healthier body composition. For research teams exploring the nuances of anabolic signaling, IGF-1 assays are a useful endpoint to correlate with fat-loss and metabolic data.
Research also suggests a relationship between GHRH analog treatment and cognitive outcomes. Baker et al. (Archives of Neurology, 2012, PMID 22869065) found that GHRH analog administration in a 137-person RCT significantly improved executive function (P=0.005) and increased IGF-1 by 117% into physiological range. More recently, Ellis et al. (Journal of Infectious Diseases, 2025, PMID 39813152) tested tesamorelin for neurocognitive impairment in 73 HIV-positive abdominally obese adults over 6 months; tesamorelin significantly reduced waist circumference (median −2.7 cm, P=0.015), but cognitive improvement trended without reaching statistical significance (P=0.06 vs. P=0.673 between groups). For research purposes, these findings suggest tesamorelin’s IGF-1-mediated metabolic effects are consistent, while cognitive endpoints in this population require further investigation[6][7].
Real-World Research: Body Composition Outcomes
Clinical studies highlight that Tesamorelin consistently reduces abdominal visceral fat, and this benefit persists with continued use. Unlike many interventions where “yo-yo” effects are common, the fat reduction seen here is sustained when peptide exposure continues[2]. This reliability is crucial for research applications where metabolic studies run for several months.
Beyond fat loss, registered trials report incremental changes in waist circumference, improved lipid profiles, and—in some cases—modest gains in lean muscle mass. The 2026 Badran et al. meta-analysis (PMID 41545261) confirms these findings across five RCTs, with a mean lean body mass increase of 1.42 kg and waist circumference reduction of 1.61 cm, without significant changes in subcutaneous fat or adverse metabolic parameters[5]. This consistent improvement in body composition makes Tesamorelin a valuable reference compound for metabolic and endocrinology research.
Related Peptides for Research: AOD9604 and Lipolysis
For those investigating fat metabolism from various angles, AOD9604 (available at OathPeptides.com) is another synthetic peptide derived from hGH. AOD9604 has a distinct mechanism, directly stimulating lipolysis without influencing IGF-1 production, making it a meaningful comparator for Tesamorelin in metabolic studies. Check out AOD9604 for your research needs here.
Maximizing Research Validity: Bacteriostatic Water and Study Controls
Optimal results for your peptide research depend on proper reconstitution and storage. We recommend using only verified Bacteriostatic Water to ensure peptide stability and experimental consistency—find it in our catalog here.
FAQs: GH-Releasing Tesamorelin for Research
Q1: What is Tesamorelin and what makes it a unique gh-releasing peptide?
Tesamorelin is a synthetic analog of GHRH, designed to trigger the pituitary gland to secrete natural growth hormone. Its main distinction is the selective reduction of visceral fat, making it a well-regarded peptide for metabolic and body composition research[2].
Q2: How does Tesamorelin affect visceral fat compared to other approaches?
Unlike classic weight-loss interventions, Tesamorelin preferentially reduces deep abdominal (visceral) fat, often with minimal impact on subcutaneous fat. A 2026 meta-analysis (PMID 41545261) pooling five RCTs quantified this effect at a mean 27.71 cm² reduction in visceral fat[5].
Q3: What are the metabolic impacts of increased GH and IGF-1 from Tesamorelin?
Tesamorelin increases both GH and IGF-1, leading to heightened fat breakdown (lipolysis), improved energy utilization, and better preservation of lean muscle mass, all essential for healthy body composition.
Q4: Is Tesamorelin available for personal use?
No. All Tesamorelin and similar gh-releasing peptides from OathPeptides.com are provided strictly for research purposes and are not for human or animal use.
Q5: How can I ensure my peptide research is consistent?
Always source peptides from reputable suppliers and use proper controls, including verified bacteriostatic water and matched comparator peptides such as CJC-1295/Ipamorelin or AOD9604.
Conclusion: Partner with Oath Research for Cutting-Edge Peptide Solutions
GH-releasing Tesamorelin is leading the way in research on visceral fat reduction and enhanced metabolic health. Its ability to target deep abdominal adipose stores, stimulate lipolysis, preserve lean mass, and increase IGF-1 levels positions it as a gold standard for metabolic and body composition science.
Whether you’re advancing laboratory knowledge of peptide action or designing protocols to probe fat metabolism, Oath Research provides rigorously tested Tesamorelin and other verified peptides for experimental use. Explore our range of research-only compounds, including Tesamorelin, AOD9604, and Bacteriostatic Water—and trust our team for expertise, reliability, and compliance.
All products are strictly for research purposes and not for human or animal use.
—
References
1. Stanley TL, et al. “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.” JAMA. 2014. PubMed
2. Stanley TL, et al. “Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial.” Lancet HIV. 2019. PubMed
3. Russo HA, et al. “Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.” AIDS. 2024. PubMed
4. Stanley TL, et al. “Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial.” Lancet HIV. 2019. PubMed
5. Badran M, et al. “Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.” Obesity Research and Clinical Practice. 2026. PubMed
6. Baker LD, et al. “Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults.” Archives of Neurology. 2012. PubMed
7. Ellis RJ, et al. “Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.” Journal of Infectious Diseases. 2025. PubMed
For more peptide research insights and to browse our catalog, visit OathPeptides.com.
Related Posts
Will BPC-157 Help Rotator Cuff Injuries?
Rotator cuff injuries affect millions of people annually, ranging from athletes to weekend warriors to office workers. These shoulder injuries can be particularly challenging to heal due to the poor vascularization of tendon tissue. Recently, researchers have turned their attention to BPC-157, a synthetic peptide derived from a protective protein found in gastric juice, as …
Oxytocin Receptor Signaling: G-Protein Coupling and Downstream Effector Pathways
A review of oxytocin receptor (OXTR) signaling mechanisms covering G-protein coupling selectivity, downstream second messenger generation, beta-arrestin recruitment, receptor desensitization kinetics, and the emerging concept of biased agonism at this class A GPCR.
Epithalon Peptide: Anti-Aging for Longevity
Curious about how telomerase and epithalon peptide could redefine anti-aging and longevity? Explore the science behind maintaining optimal cellular health, circadian balance, and your lifelong wellness journey.
Thymosin Alpha‑1: Stunning Immune Peptide Trials Revealed
Exciting clinical trials have put thymosin alpha‑1, a powerful immune peptide, in the spotlight for its impressive ability to boost the body’s natural defenses. Discover how recent breakthroughs are reshaping immune peptide research and opening new doors for disease prevention strategies.